Early Detection

What Early Detection does

Early Detection, Inc. (EDI) is a development-stage medical diagnostics company incorporated in Nevada and operating from San Diego, California. The company is developing a single product, EarlyTest, which it describes as the world's first point-of-care cancer screening test, designed to be administered in a doctor's office and intended to detect cancer at all stages of disease as well as identify risk of future cancers. The company serves healthcare providers and medical practices as the intended distribution channel, with patients as end users. No underlying technology platform, clinical methodology, biomarker panel, or device architecture is publicly described in the source material, and no patents, peer-reviewed publications, clinical trial results, or regulatory filings are disclosed.

The intended business model is a sales-led, B2B2C distribution in which the company would generate revenue through one-time sale of diagnostic test kits to physicians and medical practices. The product has not yet been commercialized, and the company is pre-revenue. The company is privately held with no disclosed funding rounds, institutional investors, headcount, management team, executive leadership, partnerships, awards, or third-party endorsements on record. Its public presence is limited to a Squarespace-hosted website at cancer.us, a LinkedIn company page, a registered office in Carson City, Nevada, and a mailing address in Coronado, California. The terms of use restrict the intended audience to US residents, indicating a US-only commercial focus at this stage. The aggregate evidence base supporting Early Detection's clinical and commercial viability is thin and consists almost entirely of first-party, self-published marketing claims.

Name

Early Detection

Legal name

Early Detection, Inc.

Website

https://cancer.us

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Early Detection is a development-stage diagnostics company building EarlyTest, a point-of-care cancer screening test for use in doctors' offices, intended to detect cancer at all stages and future cancer risk; it is pre-revenue and pre-commercialization.

Ownership category

akta.pro rank

Product category

Cancer Diagnostic Devices

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industry

Risk Stratification, Early Warning Scores & Predictive Analytics (HLACAGAE)

Keywords

• Cancer screening diagnostics
• Point-of-care testing
• Early cancer detection
• Medical diagnostic devices
• Cancer risk assessment

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. EarlyTest diagnostic test: The company is developing a medical diagnostic product (EarlyTest) for cancer screening. As a point-of-care diagnostic test, revenue would likely be generated through sale of test kits to healthcare providers and medical practices. The product is still in development phase.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Early Detection is developing EarlyTest, a point-of-care cancer screening test administered directly in a doctor's office. The product is designed to detect cancer at all stages of disease progression and identify the risk of future cancers before they develop. The test is intended to be sold to healthcare providers and medical practices as a screening tool used in routine patient care.

Product overview

Early Detection is developing a single unified product called EarlyTest, described as the world's first point-of-care cancer screening test. The product is designed to be administered directly in a doctor's office, enabling patients to detect cancer at all stages and identify risk of future cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• EarlyTest A point-of-care cancer screening test designed to detect cancer at all stages of disease progression and assess the risk of future cancers, administered directly in a doctor's office setting and intended for use by healthcare providers and their patients.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• GRAIL: GRAIL develops the Galleri multi-cancer early detection test. It is the most direct competitor to Early Detection's EarlyTest, as both target multi-cancer screening in a blood-based format, though GRAIL currently ships to a lab rather than at point of care.
• Exact Sciences: Exact Sciences markets Cologuard, the leading non-invasive colorectal cancer screening test, and acquired Thrive Earlier Detection. It is a direct peer in non-invasive cancer screening diagnostics targeting primary-care prescribing.
• Guardant Health: Guardant Health offers liquid biopsy-based oncology tests including Guardant360 and the Shield colorectal cancer screening test. It directly competes with Early Detection in blood-based cancer detection and screening.
• Freenome: Freenome is developing a multi-cancer early detection test using a blood-based multimodal approach. It is an emerging direct peer pursuing similar early-detection screening goals to EarlyTest.
• Natera: Natera's Signatera is a leading tumor-informed minimal residual disease (MRD) and recurrence monitoring test. It is comparable as an oncology blood-based diagnostic developer pursuing screening-adjacent use cases.

Emerging players

• Thrive Earlier Detection: Thrive developed a blood-based multi-cancer screening test (CancerSEEK) and was acquired by Exact Sciences. It is a comparable emerging player in multi-cancer early detection.

Broad incumbents

• Hologic: Hologic is a large diagnostics and medical device company with a women's health and molecular diagnostics franchise (e.g., ThinPrep, Panther platform). It represents a broad incumbent with overlapping diagnostic capabilities.
• Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory networks in the US, offering a broad menu of cancer diagnostics. It is a broad incumbent whose screening franchise could compete with or distribute for point-of-care cancer tests.
• Laboratory Corporation of America (Labcorp): Labcorp is a major US clinical laboratory offering cancer screening and diagnostic services. It is a broad incumbent comparable on the diagnostics delivery model rather than product technology.
• Bio-Techne: Bio-Techne is a life sciences tools and diagnostics company with a portfolio of cancer-related reagents and assay platforms (e.g., ExoDx). It is a broad incumbent in cancer diagnostics with comparable technology overlaps.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/earlydetection
• Facebookfacebook.com/Early-Detection-101608521428087

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Early Detection